Skip to main content
    C

    Curis Inc (CRIS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.51
    -0.09 (-15.31%)

    Market Cap: $1.49M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(19/38)
    Avg Surprise
    -256.54%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-2.01
    Range$-2.29 - $-1.73
    2 analysts
    EPS RevisionsNo revisions (7d)
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-6.73+70.1%
    60d ago$-6.73+70.1%
    30d ago$-6.73+70.1%
    7d ago$-5.06+60.3%
    Current$-2.01
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-16.27
    Range$-24.97 - $-8.14
    3 analysts
    Revenue Consensus
    $-2615000
    Range$-2615000 - $-2615000
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-16.27---
    Sep 26EST
    		-$-2.01---
    Jun 26
    Reported Aug 14
    		$-4.02$-5.70+29.47%Beat+70.4%
    Mar 26
    Reported May 12
    		$-25.00$-5.80-331.03%Miss+0.0%
    Dec 25
    Reported Mar 19
    		$-9.95$-8.65-15.01%Miss-695.8%
    Sep 25
    Reported Nov 6
    		$-9.80$-12.00+18.33%Beat+71.2%
    Jun 25
    Reported Aug 5
    		$-13.60N/A+55.12%Beat+66.5%
    Mar 25
    Reported May 6
    		$-25.00$-25.27+1.07%Beat+39.0%
    Dec 24
    Reported Mar 31
    		$-1.25$-0.99-26.26%Miss+96.9%
    Sep 24
    Reported Nov 14
    		$-34.00$-38.16+10.90%Beat+20.2%
    Jun 24
    Reported Aug 1
    		$-40.60$-36.20-12.15%Miss+15.4%
    Mar 24
    Reported May 7
    		$-41.00$-42.44+3.39%Beat+14.6%
    Dec 23
    Reported Feb 8
    		$-40.60$-43.93+7.58%Beat-33733.3%
    Sep 23
    Reported Nov 2
    		$-42.60$-47.15+9.65%Beat+23.9%
    Jun 23
    Reported Aug 3
    		$-48.00$-47.00-2.13%Miss+29.4%
    Mar 23
    Reported May 4
    		$-48.00$-43.00-11.63%Miss+33.3%
    Dec 22
    Reported Mar 13
    		$-0.12$-0.13+7.69%Beat+20.0%
    Sep 22
    Reported Nov 9
    		$-56.00$-68.00+17.65%Beat-16.7%
    Jun 22
    Reported Aug 4
    		$-68.00$-66.00-3.03%Miss-41.7%
    Mar 22
    Reported May 5
    		$-72.00$-64.00-12.50%Miss-63.6%
    Dec 21
    Reported Feb 24
    		$-0.15$-0.13-15.38%Miss-36.4%
    Sep 21
    Reported Nov 9
    		$-48.00$-52.00+7.69%Beat-9.1%
    Jun 21
    Reported Aug 3
    		$-48.00$-44.00-9.09%Miss+29.4%
    Mar 21
    Reported May 12
    		$-44.00$-37.00-18.92%Miss-15614.3%
    Dec 20
    Reported Mar 16
    		$-0.11$-0.09-22.22%Miss+97.9%
    Sep 20
    Reported Nov 10
    		$-44.00$-68.00+35.29%Beat-1057.9%
    Jun 20
    Reported Aug 4
    		$-68.00$-80.00+15.00%Beat-1445.5%
    Mar 20
    Reported May 12
    		$-0.28N/AN/ABeat+95.3%
    Dec 19
    Reported Mar 19
    		$-5.20$-0.20-2500.00%Miss+92.8%
    Sep 19
    Reported Nov 5
    		$-3.80$-0.20-1800.00%Miss+95.7%
    Jun 19
    Reported Aug 6
    		$-4.40$-0.19-2215.79%Miss+95.8%
    Mar 19
    Reported May 14
    		$-6.00$-0.19-3057.89%Miss+95.7%
    Dec 18
    Reported Mar 26
    		$-72.00$-84.00+14.29%Beat-28700.0%
    Sep 18
    Reported Nov 1
    		$-88.00$-122.67+28.26%Beat+60.0%
    Jun 18
    Reported Aug 2
    		$-104.00$-153.33+32.17%Beat+48.0%
    Mar 18
    Reported May 3
    		$-140.00$-140.00+0.00%Beat+36.4%
    Dec 17
    Reported Mar 8
    		$-0.25$-0.45+44.44%Beat+37.5%
    Sep 17
    Reported Nov 7
    		$-220.00$-186.67-17.86%Miss-
    Jun 17
    Reported Aug 3
    		$-200.00$-186.67-7.14%Miss-
    Mar 17
    Reported May 4
    		$-220.00$-173.33-26.93%Miss-
    Dec 16
    Reported Mar 9
    		$-0.40$-0.49+18.37%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.01EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-833.00%
    ROE-694.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio0.49xQuick Ratio0.49x
    Trading Statistics
    Beta3.10Avg Volume202.41K
    52-Week High$33.6052-Week Low$0.59

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.68
    SMA 20$0.79
    SMA 50$1.36
    SMA 200$10.04
    EMA 10$0.67
    EMA 20$0.83
    EMA 50$1.83
    EMA 200$9.65

    MACD

    Line: -0.27Signal: -0.30Hist: 0.04

    ADX

    ADX: 57.8+DI: 4.5-DI: 28.8

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down100.0
    PSAR$0.81

    Bollinger Bands

    Upper Band$1.06
    Lower Band$0.51
    %B Position6959%(Upper)
    Band Width-0.01

    RSI (14-Day)

    Oversold
    10.6

    Momentum Oscillators

    Stoch %K7.9
    Stoch %D7.9
    Williams %R-89.1
    ROC (10d)-38.8%
    Momentum-0.32
    CCI (20d)-161.4
    MFI (14d)4.2

    Volatility Measures

    ATR (14d)$0.15(29.3%)
    StdDev (20d)0.14
    Hist Vol62.0%(High)

    Volume Flow

    VWAP$0.53
    OBV124.3M
    AD Line43.4B
    CMF (20d)-0.293

    Volume Metrics

    Avg Vol (20d)206.7K
    Vol Ratio2.3x(High)
    VWMA (20d)$0.77

    Pivot Points

    R3$0.67
    R2$0.64
    R1$0.62
    Pivot Point$0.60
    S1$0.58
    S2$0.55
    S3$0.53

    Advanced Oscillators

    TSI-72.62
    Ultimate Osc34.7
    KST-440.33

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$1.14M$3.18M$2.75M$2.38M$3.35M$2.93M$2.55M$2.09M$2.70M$2.83M
    Cost of Revenue$0$0$36,000$0$0$0$17,000$0$0$0$-24,000$0
    Gross Profit$0$0$1.14M$3.18M$2.75M$2.38M$3.35M$2.93M$2.55M$2.09M$2.72M$2.83M
    Operating Expenses$9.94M$11.52M$-18,481,000$10.10M$11.00M$12.54M$12.34M$13.50M$15.06M$14.55M$14.92M$15.20M
    R&D$6.71M$6.45M$5.83M$6.43M$7.46M$8.54M$8.97M$9.72M$10.25M$9.62M$9.96M$10.38M
    SG&A$3.23M$5.07M$2.88M$3.65M$3.53M$3.98M$3.35M$3.75M$4.79M$4.89M$4.88M$4.76M
    Operating Income$-9,940,000$-11,519,000$19.62M$-6,924,000$-8,251,000$-10,157,000$-8,994,000$-10,567,000$-12,512,000$-12,469,000$-12,199,000$-12,368,000
    Interest Income$62,000$77,000$51,000$80,000$92,000$93,000$227,000$325,000$701,000$515,000$665,000$806,000
    Interest Expense$0$12.68M$263,000$885,000$434,000$552,000$624,000$0$-8,000$0$0$619,000
    Income Before Tax$-8,581,000$-24,199,000$19.36M$-7,729,000$-8,593,000$-10,616,000$-9,618,000$-10,092,000$-11,803,000$-11,876,000$-11,780,000$-12,181,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-8,581,000$-24,199,000$19.36M$-7,729,000$-8,593,000$-10,616,000$-9,618,000$-10,092,000$-11,803,000$-11,876,000$-11,712,000$-12,181,000
    EBITDA$-8,635,000$-24,268,000$19.66M$-6,892,000$-8,209,000$-10,098,000$-8,550,000$-10,350,000$-12,984,000$-12,243,000$-12,150,000$-12,747,000
    EBIT$-8,643,000$-24,276,000$19.62M$-6,924,000$-8,251,000$-10,157,000$-8,994,000$-10,417,000$-12,512,000$-12,391,000$-12,199,000$-12,368,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CRIS

    News

    November 5, 2026 earnings date gives Curis stock a USD 1.00 million estimate

    Curis (CRIS) is projected to report its third-quarter 2026 results on November 5, 2026, with an estimated revenue of USD 1.00 million. The company reported a net loss of USD 8.6 million in Q2 2026 and held USD 5.1...

    ad-hoc-news.de•10/15/26•Neutral

    November 5, 2026 earnings date gives Curis stock a USD 1.00 million estimate

    Curis (CRIS) is expected to report its third-quarter 2026 results on November 5, 2026, with an estimated revenue of USD 1.00 million. The company reported a net loss of USD 8.6 million in Q2 2026 and held USD 5.1 million...

    ad-hoc-news.de•10/15/26•Somewhat-Bearish

    Curis priced a USD 5.6 million offering and Curis stock fell 10.61 percent

    Curis announced that it had priced a $5.6 million public offering, leading to a 10.61% drop in its stock price to EUR 0.59 on October 8, 2026. Despite the stock decline...

    AD HOC NEWS•10/8/26•Somewhat-Bearish

    Curis (CRIS) Earnings Results: Cash Runway Is the Main Investor Test

    Curis (CRIS) reported no revenue in Q2 2026 after selling Erivedge royalty rights, making its financial viability dependent on clinical progress for emavusertib and access to capital. Despite reduced operating expenses...

    AlphaStreet•10/7/26•Bearish

    Curis stock fell 5.07 percent as targets reached USD 65

    Curis (CRIS) stock fell 5.07% to USD 0.75, trading near its 52-week low despite analysts maintaining a "Strong Buy" consensus with an average target of USD 42.6667. The biotechnology company is advancing its central...

    AD HOC NEWS•10/6/26•Bearish

    CRIS Valuation and Fair Value

    P/E
    -0.0x
    PEG
    0.0x
    P/B
    0.2x
    See GNG's fair value

    CRIS Profitability: Margins, ROIC and FCF

    Operating margin
    -833.0%
    Net margin
    0.0%
    ROE
    -694.0%
    FCF margin
    -709.0%

    CRIS Competitors

    CompanyTicker
    Oragenics IncOGEN
    Protagenic TherapeuticsPTIX
    Genprex IncGNPX
    Iterum Therapeutics PLCITRM
    Nexgel IncNXGL
    Mobile-health Network Solutions Class A Ordinary SharesMNDR
    Purple BiotechPPBT
    VSee Health, Inc.VSEE

    Sector: Healthcare

    CRIS Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    1
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    CRIS Bull Case vs Bear Case

    Bear case

    • CRIS's quarterly revenue changed -66.0% year over year.

    CRIS Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    -32.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-2.01
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About CRIS

    Does CRIS pay dividends?

    Curis Inc (CRIS) does not currently pay a regular dividend.

    What is CRIS's market cap?

    Curis Inc (CRIS) has a market capitalization of $1.49M with a current stock price of $0.51.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In